Objective To determine whether gonadotropin releasing hormone (GnRH)-agonist or -antagonist induces higher percentages of cumulus cell apoptosis and if the use of either is detrimental to ART outcomes. Patients Women in a private facility under treatment for IVF had their cumulus cells isolated and analyzed by flow cytometry. Viable, apoptotic, and dead cumulus cell rates related to ovarian stimulation by GnRH-agonist orantagonist were measured and compared with fertilization and implantation rates. Results Treatment with GnRH-agonist produced a greater number of follicles than treatment with GnRH-antagonist. No differences in implantation and pregnancy rates were found. While cumulus cell (CC) apoptosis was positively correlated with estradiol on the day of hCG administration, no significant difference in the percentage of apoptotic cells between treatments was detectable. Additionally, implantation rate and the average follicular estradiol production on the day of hCG administration were no different between treatments.
Introduction
Controlled ovarian stimulation (COS), used for development of multiple ovarian follicles per cycle, is widely implemented with Assisted Reproduction Technology (ART). Specifically, COS is achieved by administering exogenous FSH to develop supra-numerary follicles until they reach the proper size for final maturation. One risk of this process is unintended ovulation in response to the endogenous hormonal environment. Administration of GnRH-agonist orantagonist can eliminate this risk and avoid premature ovulation [1] . It has been speculated that administration of exogenous gonadotropin results in supra-numerary follicles by overriding a natural process: selection of a dominant follicle and subsequent follicular atresia of subordinate follicles [2] , which occurs through apoptosis initiated in the granulosa cells [3] [4] [5] [6] . Granulosa cells (GCs), and their specialized oocyte-communicating counterpart cumulus cells (CCs), play an important role in essential oocyte maturation processes [7] . GC apoptosis and/or necrosis may influence oocyte quality and future embryo development. Studies have reported a positive correlation of GC number with poor IVF/ICSI results [8] [9] [10] [11] [12] [13] .
Conflicting information exists regarding the effects of endogenous gonadotropin down-regulation and GC apo-ptosis. Assessment of GC death, suspended in the follicular fluid, reveled that the mechanism of GnRH-induced downregulation did not influence GC survival [2] . However, studies assessing mural GC apoptosis revealed that programmed cell death is more common in treatments with GnRH agonist + human menopausal gonadotropin (hMG) + hCG than in hMG + hCG or spontaneous cycles [8] . Cultured luteinized granulosa cells exposed to a GnRHagonist, Leuprolide acetate, suffered DNA synthesis inhibition and were more susceptible to apoptosis than those exposed to a GnRH-antagonist [9] . Interestingly, Corn et al. evaluated apoptosis in cumulus cells in relation to blastocyst development without considering the mode of GnRH down-regulation [14] . Therefore, we sought to verify whether controlled ovarian stimulation with GnRH-agonist or -antagonist induces apoptosis in cumulus cells, and if the percentage of apoptosis has significant detrimental impacts on fertilization or implantation rates.
Materials and methods
This prospective observational study was composed of 35 women undergoing controlled ovarian stimulation as follows:
1. Delivery of recombinant-hFSH beginning on either day 2 or 3 of the menstrual cycle, continuing with a full dose until ≥2 codominant follicles reached 18 mm in the largest diameter as measured by transvaginal ultrasonography. When two codominant follicles reached 13-14 mm or the patient reached day 6 of stimulation, a daily subcutaneous SC injection of 0.25 mg Cetrotide (CTD) was initiated.
From the first day of CTD treatment until the day of maturational hCG administration, the patient returned to the clinic at least every two days for ultrasound imaging and blood sampling. [15] . 2. Daily SC injections of Leuprolide acetate (0.5 mg;
Reliser®, Serono Laboratories, Inc.) were administered in the midluteal phase of the previous menstrual cycle to cause pituitary desensitization, after which recombinant hFSH was initiated. The criteria for pituitary desensitization were met when women began menstrual flow accompanied by serum E 2 levels <60 pg/mL in the absence of ovarian cysts (>10 mm) and exhibited an endometrial thickness <3 mm by transvaginal sonography [15] .
Administration of either the GnRH antagonist or the GnRH agonist was extended until the day of final follicle maturation (defined by ultrasonic detection of ≥2 follicles >18 mm in diameter). Subsequently, a maturational dose of 10,000 IU of urinary hCG (Profasi ® , Serono Laboratories, Inc.) was injected to accommodate oocyte retrieval within 35-36 h [15] . Patients were assigned to yield a ratio of 1:2 follicles produced by agonist:antagonist. Information was collected regarding the patient's age, basal FSH, estradiol and progesterone concentrations (basal and on hCG day), total FSH dose, and number of follicles.
Retrieved oocyte cumulus complexes (OCCs) were cultured for 4 h prior to removal of the cumulus cells. Mature oocyte cumulus complexes were individualized in 250 µL G1 (VitroLife, Sweden) droplets and were transferred to denudation medium containing 80 IU/mL of hyaluronidase. Pasteur pipettes were used to gently manipulate oocyte cumulus complexes and remove cumulus cells. Single cell suspensions and hyaluronidase wash-out were obtained by three washes in PBS [16] . Cumulus cells were dispersed in a dilution buffer to a concentration < 1.10 5 cells/mL, and an unstained aliquot was subjected to flow cytometry for equipment calibration. Fifty microliters of cell suspensions were incubated with 450 µL ViaCount reagent (Guava Technologies Inc., California, USA) for 5 min. After staining, samples were loaded into sample tubes and subjected to flow cytometry (Guava PC, Guava Technologies Inc., California, USA) until all cells were counted or a maximum of 10,000 cells was reached. Analysis for individualized oocyte cumulus complexes was performed with Cytosoft in ViaCount mode (Guava Technologies Inc., California, USA). Cytograms discriminating live and dead cells were also obtained.
Oocytes were evaluated, and mature metaphase II oocytes were inseminated by sperm injection. Fertilized zygotes and subsequent embryos were cultured within individual microdrops until morphologic selection [17] of one to four embryos per patient. Fluorescence-activated cell sorting analysis of viable, apoptotic and dead cells for each OCC was done after cell staining with Guava ViaCount Reagent following the manufacturer's instructions and using a Guava PCA flow cytometer. The percentages of viable, apoptotic and dead cells per OCC were calculated with Cytosoft software (version 2.1.4, Guava Technologies, Inc, California, USA). Pearson's correlation coefficients were calculated for the percentages of viable, apoptotic, and dead CCs from the oocytes resulting in transferred embryos in relation to the patient's basal FSH, estradiol and progesterone concentrations (basal and on hCG day), total FSH dose and implantation rate [18] . These data sets were split into GnRH-agonist and GnRH-antagonist groups for comparison. All data were analyzed using a KolmogorovSmirnov normality test,F-test for variance homogeneity and Student's t test for differences in means. Differences were considered significant at p<0.05 [18] .
Results
Patients assigned to treatment with GnRH-agonist (9 patients; 76 OCCs) and GnRH-antagonist (26 patients; 162 OCCs) protocols were of similar ages at the time of their treatment (37±1.6 vs. 37±0.8 years), and no differences in their basal hormonal profiles were observed. Differences in the total FSH doses administered per patient were not significant between groups. Serum concentrations of estradiol and progesterone on the day of hCG administration were not significantly altered, despite the higher number of follicles in the agonist group. Fertilization, number of transferred embryos, implantation and pregnancy rates were similar between the two groups, and gonadotropin-releasing hormone modality produced no differences in the percentage of viable, apoptotic and dead CCs (Table 1) .
Estradiol concentration on hCG day and estradiol per follicle were positively correlated with the percentage of apoptotic CCs. Fertilization rates correlated with percentages of viable and dead cells, and implantation rates were positively and negatively correlated to percentages of apoptotic and dead cells, respectively. Pearson's correlation coefficient values are shown in Table 2 .
Discussion
We found that treatment with GnRH-agonist or -antagonist did not significantly increase the apoptotic population of CCs associated with oocytes. These results are similar to those of Giampietro and colleagues [2] who reported similar levels of apoptosis in granulosa cells suspended in follicular fluid using an Annexin V/PI flow cytometry assay. However, experimental differences exist between these two studies. Cells examined in the previous study were from follicular fluid, while our study examined detached cells directly from OCCs. Greater than 99.9% of the follicles present at birth are destined to die via apoptosis during reproductive life [19] . Typically, cytoplasmic blebbing and catalytic cleavage events featured during apoptosis commonly lead to loss of function. However, in the cells of the inner layer of the ovarian follicle, the steroidogenic function is preserved through actin migration and a cytoplasmic compartmentalization that segregates and protects steroidogenic machinery from proteosomes activated in the executioner pathways of apoptosis [20] [21] [22] [23] . We found a subtle positive correlation between estradiol and apoptosis, as was reported in a study showing that cultured granulosa cells had an increment in steroidogenesis during programmed cell death [21] . However, we did not find a correlation between progesterone levels on hCG day and the percentage of apoptotic cells. The shift in steroid production probably relies on the dose of FSH used during stimulation, which influences GC estrogenic pathways [24] .
Previous studies have investigated the incidence of GC apoptosis and its relation to IVF/ICSI results [8] [9] [10] [11] [12] [13] . However, it is important to recognize that the majority of these studies assessed apoptosis of cells suspended in follicular aspirates. Those values represent an evaluation of apoptosis within the mural granulosa cells that detached from the follicular wall during follicle aspiration [9] [10] [11] [12] [13] . Mural granulosa cells are protected from apoptosis by bFGF-acting as a survival factor -sequestered in the basal lamina [19] . Thus, apoptosis of mural cells obtained from an individual follicle can be viewed as an impairment factor. Since apoptosis takes place even with the protective effect of bFGF, this might indicate that the follicle is undergoing atresia. In natural cycles, apoptosis occurs in cells from large follicles in an asynchronous pattern, probably due to differences in cell cycle stages. However, in cycles under controlled ovarian stimulation, evaluation of granulosa cell cycle revealed that the majority of cells were in G0/G1 stages, indicating a synchronization among the cells during a stage in which they are more susceptible to programmed cell death [1] .
Our results led us to hypothesized that apoptosis in CCs from follicles under controlled ovarian stimulation were a sign of maturity and differentiation of the follicle rather than poor developmental potential of oocytes. The observed percentage of apoptotic cells correlated with the implantation rate supports our hypothesis. However, in this study, we based embryo selection on standard morphology features since using apoptosis in cumulus cells as a marker of oocyte developmental potential remains under debate. In conclusion, GnRH-agonist or antagonist treatment protocols induce similar levels of apoptosis in CCs, and this cell death is not detrimental to ART outcomes.
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